ERBB2 and neoplasm: Other studies based on incidence of brain involvement among patients with metastatic HER-2 positive tumor has been reported to be from 25 to 34% [18], which is significantly higher than the 3.4 and 1.9% rate for triple negative and HR−/HER2+ subtypes respectively in another study [8].